NASDAQ:CVAC CureVac Q1 2023 Earnings Report $4.77 +0.33 (+7.52%) As of 02:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast CureVac EPS ResultsActual EPS-$0.29Consensus EPS -$0.29Beat/MissMet ExpectationsOne Year Ago EPSN/ACureVac Revenue ResultsActual Revenue$7.65 millionExpected Revenue$16.45 millionBeat/MissMissed by -$8.80 millionYoY Revenue GrowthN/ACureVac Announcement DetailsQuarterQ1 2023Date5/30/2023TimeN/AConference Call DateTuesday, May 30, 2023Conference Call Time7:00AM ETUpcoming EarningsCureVac's Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Thursday, August 14, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) CureVac Earnings HeadlinesJMP Securities Reiterates "Market Outperform" Rating for CureVac (NASDAQ:CVAC)May 29 at 2:01 AM | americanbankingnews.comWe Think CureVac's (NASDAQ:CVAC) Robust Earnings Are ConservativeMay 27 at 4:27 PM | finance.yahoo.comElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.May 29, 2025 | Brownstone Research (Ad)CureVac FY2025 EPS Forecast Increased by Leerink PartnrsMay 24, 2025 | americanbankingnews.comEarnings Beat: CureVac N.V. (NASDAQ:CVAC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 23, 2025 | finance.yahoo.comCautious Hold Rating for CureVac Amid Uncertain Revenue ProjectionsMay 23, 2025 | tipranks.comSee More CureVac Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CureVac? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CureVac and other key companies, straight to your email. Email Address About CureVacCureVac (NASDAQ:CVAC) N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.View CureVac ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles CrowdStrike Stock Slips: Analyst Downgrades Before Earnings Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAdvance Auto Parts: Did Earnings Defuse Tariff Concerns?Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Upcoming Earnings CrowdStrike (6/3/2025)Haleon (6/4/2025)Broadcom (6/5/2025)Oracle (6/10/2025)Adobe (6/12/2025)Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
